Kamal A, Koch I M
Eur J Rheumatol Inflamm. 1982;5(2):76-81.
Benoxaprofen plasma profiles were obtained in 10 elderly patients (mean age 77 years) suffering from osteoarthritis and various underlying diseases. Blood levels were measured over a 17-day period. Benoxaprofen, 600 mg, was given daily for the first 10 days. The mean peak plasma concentration on Day 1 occurred three hours after the fasting dose. Mean plasma levels on Days 2-10 showed a continuing rise with no indication that a steady-state level was achieved. Elimination half-lives calculated from plasma levels on Days 12-17 resulted in a mean of 101 hours in these elderly patients. This is a substantial increase compared with normal subjects (half-life 30 to 35 hours). Most haematologic and biochemical results were judged to be within the usual range for this type of elderly patient (A.K.) No evidence of renal impairment due to the treatment was shown. The higher benoxaprofen concentrations and the long elimination half-life show evidence of accumulation in the elderly, probably due to several causes, including poor bowel motility and decreased renal clearance common with increasing age. The recommended dose may require modification in geriatric patients.
在10名患有骨关节炎及多种基础疾病的老年患者(平均年龄77岁)中获取了苯恶洛芬的血浆浓度曲线。在17天的时间内测量血药浓度。前10天每天给予600毫克苯恶洛芬。空腹给药后,第1天的平均血浆峰浓度在3小时后出现。第2 - 10天的平均血浆浓度持续上升,没有迹象表明达到了稳态水平。根据第12 - 17天的血浆浓度计算出的消除半衰期,这些老年患者的平均值为101小时。与正常受试者(半衰期30至35小时)相比,这有显著增加。大多数血液学和生化检查结果被判定在这类老年患者(A.K.)的正常范围内。未显示出因治疗导致肾功能损害的证据。苯恶洛芬浓度较高且消除半衰期较长表明在老年人中存在蓄积现象,可能是由多种原因导致的,包括肠道蠕动不佳以及随着年龄增长常见的肾清除率降低。老年患者可能需要调整推荐剂量。